Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Improved survival with intermediate-intensity pediatric-inspired regimen and allo-HSCT in adults with ALL in a resource-limited setting

Eduardo Chapchap, Pedro Perez, André Américo, Renata Queiroz, Maria Luíza Dourado, Vinicius de Molla, Celso Arrais-Rodrigues, Alex Sandes, Fabio Kerbauy

Blood (2025) 146 (Supplement 1): 5106.

https://doi.org/10.1182/blood-2025-5106

Published: 2025

Journal Articles

Xgboost model using diagnostic CBC to predict early mortality in newly diagnosed AML patients

Pedro Perez, André Shimaoka, Antonio da Silva-Junior, José Marcio Duarte, Renata Queiroz, André Américo, Maria Luíza Dourado, Vinicius de Molla, Gabriel Cunha, Celso Arrais-Rodrigues, Fabio Kerbauy, Paulo Paiva, Alex Sandes

Blood (2025) 146 (Supplement 1): 4348.

https://doi.org/10.1182/blood-2025-4348

Published: 2025

Journal Articles

Azole-adjusted venetoclax-based regimens in unfit AML patients: A real-world brazilian experience from a resource-limited setting

Pedro Perez, Renata Queiroz, André Américo, Maria Luíza Dourado, Vinicius de Molla, Gabriel Cunha, Eduardo Chapchap, Celso Arrais-Rodrigues, Alex Sandes, Fabio Kerbauy

Blood (2025) 146 (Supplement 1): 8187.

https://doi.org/10.1182/blood-2025-8187

Published: 2025

Journal Articles

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Gabriel Cunha, Pedro Perez, Fernanda Marques, Verena Pfister, Rodrigo Santucci, Milton Aranha, Danielle De Farias, Talita Silveira, Jayr Schmidt Filho, Valeria Buccheri, Roberto Silva, Leila Perobelli, Glaciano Ribeiro, Maura Colturato, Nelson Hamerschlak, Pedro Fernandes, Fernanda Santos Azevedo, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2025) 146 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2025-3909

Published: 2025

Journal Articles

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

Blood (2012) 120 (21): 4956.

https://doi.org/10.1182/blood.V120.21.4956.4956

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Improved survival with intermediate-intensity pediatric-inspired regimen and allo-HSCT in adults with ALL in a resource-limited setting

Xgboost model using diagnostic CBC to predict early mortality in newly diagnosed AML patients

Azole-adjusted venetoclax-based regimens in unfit AML patients: A real-world brazilian experience from a resource-limited setting

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

Email alerts

ASH Publications

American Society of Hematology

Update search

Improved survival with intermediate-intensity pediatric-inspired regimen and allo-HSCT in adults with ALL in a resource-limited setting

Xgboost model using diagnostic CBC to predict early mortality in newly diagnosed AML patients

Azole-adjusted venetoclax-based regimens in unfit AML patients: A real-world brazilian experience from a resource-limited setting

Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry.“

Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only